Figure 1.

Scheme representing the utility of epigenetic changes found in liquid biopsies as biomarkers for cancer diagnosis, patient’s stratification, prognosis, and response to treatments. Changes in DNA methylation of gene promoters and abnormal levels of non-coding RNAs (ncRNAs) can be found in fluids as free molecules or inside extracellular vesicles (EVs). Integration of these biological markers with clinical and radiological data may help in the management of cancer patients, in particular in the field of screening and diagnosis.